Speaker Profile

M.D., Chief Medical Officer, Multi-Cancer Early Detection, Exact Sciences

Dr. Beer is an internationally recognized leader, holding appointments as deputy director of the Knight Cancer Institute, Chief Medical Officer at OHSU’s Knight Cancer Institute Cancer Early Detection Advanced Research Center, professor in the OHSU School of Medicine, head of the Prostate Cancer Research Program, and the Grover C. Bagby Endowed Chair for Prostate Cancer Research prior to joining Exact. He has also authored and co-authored more than 280 articles, playing a leading role in establishing a new global standard of care for patients. In addition to his role at Exact Sciences, Dr. Beer is continuing as an adjunct professor of medicine and sees patients with prostate cancer at OHSU.

Framing the Future of Cancer Screening Multi-cancer Early Detection Testing
Cancer is often detected too late. MCED liquid biopsy tests are designed to harness the power of a variety of biomarkers from various tumors to help detect cancer prior to symptom onset. We’ll share the current evidence for novel multi-analyte approaches to MCED testing that, in combination with standard of care screening, may have the potential to detect more cancers at earlier stages when they are more treatable.

 Session Abstract – PMWC 2023 Silicon Valley

Track 4 - January 26 9.00 A.M.-4.30 P.M.

Track Chair: Cindy Perettie, Roche

  • PMWC 2023 Award Ceremony
    - Luis Alberto Diaz Jr., MSK
    - Razelle Kurzrock, Medical College of Wisconsin
  • Non-invasive Liquid Biopsy Techniques (PANEL)
    Chair: Razelle Kurzrock, Medical College of Wisconsin
    - Apostolia Tsimberidou, MD Anderson
    - Mandana Kamgar, MD Medical College of Wisconsin
    - Mina Nikanjam, UCSD
    - Ash Alizadeh, Stanford University
  • Liquid Biopsy Challenges and Limitations (PANEL)
    Chair: Victor Lin, Mary Bird Perkins
    - Luis Alberto Diaz Jr., MSK
    - Maximilian Diehn, Stanford
    - Dana Dilbeck, Agilent
    - Emma Shtivelman, Cancer Commons
  • Liquid Biopsy in Clinical Trials: Learnings and COVID Experience (PANEL)
    Chair: Cindy Perettie, Roche Diagnostics
    - Eric Peters, Genenetch
    - Andrew Mckenzie, Sarah Cannon
    - Yang Pan, Gilead
    - Alan Sandler, Mirati Therapeutics
  • Multi-Cancer Early Detection Through Multi-Biomarker Class Liquid Biopsy Testing
    Chair: Tom Beer, Exact Sceinces
  • Liquid Biopsy for Early Cancer Detection (PANEL)
    Chair: Priti Hegde, Foundation Medicine
    - Daniel Kim, UCSC
    - Mike Nolan, Freenome
    - Jeffrey Venstrom, Grail Bio
    - Kathryn Phillips, UCSF
    - Lon Castle, eviCore healthcare
    - Tom Beer, Exact Sciences
  • Liquid Biopsy for Minimal Residual Disease (PANEL)
    Chair: Minetta Liu, Natera
    - Peter Bach, Delfi diagnostics
    - Laura Vantveer, UCSF
    - Susan Bobulsky, Adaptive
    - Joshua Cohen, Johns Hopkins
  • PMWC Showcase
    - Harmeet Dhani, Biological Dynamics
    - Varsha Rao, Claret Bio
  • PMWC NCI Showcase
    - Xianghong Jasmine Zhou, EarlyDiagnostics